Rare diseases
Investigational molecules
Locations
P. O. Box 100, 9038 Tromsø, Norway
Universitetssykehuset Nord-Norge HF in Tromsø, Norway specialises in clinical trials of conditions such as Acute myeloid leukaemia, Colitis ulcerative, Crohn's disease, Chronic kidney disease, and other specialisations. This site conducts important research.
The medical center is at the forefront of oncology research, focusing on innovative treatments for various types of cancer. The center's work in this field is driven by a commitment to improving patient outcomes through cutting-edge therapies and personalized medicine.
Through its research, the center is advancing the understanding of cancer biology and developing new therapeutic strategies that are transforming the standard of care for cancer patients worldwide.
Specializing in neurology, the center is dedicated to exploring novel treatments for neurological disorders. Its research aims to enhance the quality of life for patients by addressing the complex challenges associated with these conditions.
The center's pioneering work in neurology is paving the way for breakthroughs in understanding and treating neurological diseases, offering hope to patients and families affected by these conditions.
In the field of cardiology, the center is leading research efforts to improve cardiovascular health. Its studies focus on innovative therapies and interventions that aim to reduce the burden of heart disease.
By advancing the understanding of cardiovascular conditions, the center is contributing to the development of more effective treatments and preventive measures, ultimately enhancing patient care and outcomes.
The center's research in immunology is focused on harnessing the power of the immune system to combat diseases. This includes exploring new immunotherapies and understanding immune responses in various conditions.
Through its innovative research, the center is making significant strides in developing therapies that modulate the immune system, offering new hope for patients with autoimmune and inflammatory diseases.
In gastroenterology, the center is committed to advancing the treatment of digestive disorders. Its research focuses on understanding the underlying mechanisms of these conditions and developing targeted therapies.
The center's work in gastroenterology is leading to new insights and treatment options that improve the lives of patients with chronic digestive diseases.
Specializing in endocrinology, the center is exploring innovative treatments for hormonal disorders. Its research aims to improve the management and outcomes of these complex conditions.
Through its research, the center is advancing the understanding of endocrine disorders and developing new therapeutic approaches that enhance patient care.
Clinical trials currently enrolling participants at this site.
NorwayRandomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease
NorwayBI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases
NorwayA study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)
NorwayA study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease
NorwayA study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease
NorwayStudy on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet
NorwayStudy of Dostarlimab After Chemoradiation for Adults with Advanced Unresected Head and Neck Cancer
NorwayEfficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis
NorwayRinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy
NorwayNipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus
NorwayN1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD
NorwayMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
